Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMAB NASDAQ:OCX NASDAQ:RCKT NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMABI-Mab$3.62-11.5%$3.41$0.60▼$5.90$295.61M1.351.01 million shs1.64 million shsOCXOncoCyte$3.18+16.3%$3.07$1.92▼$4.75$90.80M0.9758,260 shs100,514 shsRCKTRocket Pharmaceuticals$3.22+1.9%$3.16$2.19▼$22.01$347.44M0.623.61 million shs2.30 million shsUPXIUpexi$6.33-6.4%$6.31$1.90▼$22.57$372.77M-0.483.87 million shs5.17 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMABI-Mab0.00%-6.62%-16.02%+62.30%+285.85%OCXOncoCyte0.00%0.00%0.00%+16.30%+3.08%RCKTRocket Pharmaceuticals0.00%-3.66%+3.61%+9.72%-83.92%UPXIUpexi0.00%+11.92%-8.03%-31.30%+73.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMABI-Mab$3.62-11.5%$3.41$0.60▼$5.90$295.61M1.351.01 million shs1.64 million shsOCXOncoCyte$3.18+16.3%$3.07$1.92▼$4.75$90.80M0.9758,260 shs100,514 shsRCKTRocket Pharmaceuticals$3.22+1.9%$3.16$2.19▼$22.01$347.44M0.623.61 million shs2.30 million shsUPXIUpexi$6.33-6.4%$6.31$1.90▼$22.57$372.77M-0.483.87 million shs5.17 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMABI-Mab0.00%-6.62%-16.02%+62.30%+285.85%OCXOncoCyte0.00%0.00%0.00%+16.30%+3.08%RCKTRocket Pharmaceuticals0.00%-3.66%+3.61%+9.72%-83.92%UPXIUpexi0.00%+11.92%-8.03%-31.30%+73.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMABI-Mab 3.00Buy$7.0093.37% UpsideOCXOncoCyte 2.75Moderate Buy$6.0690.94% UpsideRCKTRocket Pharmaceuticals 2.41Hold$16.73419.67% UpsideUPXIUpexi 3.50Strong Buy$15.50144.87% UpsideCurrent Analyst Ratings BreakdownLatest OCX, IMAB, UPXI, and RCKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025IMABI-MabNew Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$7.009/9/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.009/8/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.008/28/2025IMABI-MabLoop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$8.008/28/2025IMABI-MabBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/21/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/20/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $6.008/20/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $10.008/20/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/13/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMABI-Mab$3.89M75.99N/AN/A$2.47 per share1.47OCXOncoCyte$3.84M23.63N/AN/A($0.70) per share-4.54RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/AUPXIUpexi$26M14.34N/AN/A$6.24 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)OCXOncoCyte-$60.66M-$3.53N/AN/AN/A-1,516.06%-215.59%-27.23%N/ARCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/29/2025 (Estimated)Latest OCX, IMAB, UPXI, and RCKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025IMABI-Mab-$0.10-$0.07+$0.03-$0.07N/AN/A8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMABI-MabN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMABI-MabN/A22.8222.82OCXOncoCyte0.203.743.70RCKTRocket Pharmaceuticals0.056.396.39UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMABI-Mab38.38%OCXOncoCyte55.35%RCKTRocket Pharmaceuticals98.39%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipIMABI-Mab22.10%OCXOncoCyte2.05%RCKTRocket Pharmaceuticals24.76%UPXIUpexi4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMABI-Mab38081.66 million63.61 millionOptionableOCXOncoCyte12028.60 million28.01 millionNo DataRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableUPXIUpexi13058.89 million56.29 millionOptionableOCX, IMAB, UPXI, and RCKT HeadlinesRecent News About These CompaniesUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateSeptember 15 at 2:29 AM | marketbeat.comUpexi Stock Pops Pre-Market, Retail Chatter Surges On Growing Solana Treasury HoldingsSeptember 12 at 10:57 AM | msn.comUpexi's Stellar Gains: Solana Treasury Strategy Drives 129% Growth in SOL ValueSeptember 12 at 5:56 AM | econotimes.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)September 11, 2025 | prnewswire.comUpexi Adjusted SOL per Share Increases 129% Since Treasury LaunchSeptember 11, 2025 | globenewswire.comSolana gains 5% as Forward Industries reveals $1.6 billion SOL treasury planSeptember 8, 2025 | fxstreet.comUpexi Engages in September 2025 Investor ConferencesSeptember 8, 2025 | tipranks.comUpexi (NASDAQ:UPXI) Stock Price Down 4.5% - What's Next?September 7, 2025 | marketbeat.comUpexi to Participate in Upcoming September ConferencesSeptember 3, 2025 | manilatimes.netMBitcoin Gains As ‘September Slump’ Remains Uncertain – Retail Traders Bet On Break From Trend In 2025September 3, 2025 | msn.comUpexi, Inc. Announces Strategic Investment in Alpha ExchangeAugust 28, 2025 | markets.businessinsider.comUpexi Invests in Alpha Exchange for Revenue ShareAugust 27, 2025 | tipranks.comUpexi Amends Securities Purchase AgreementAugust 26, 2025 | msn.comUpexi Approves Share Increase and New AgreementAugust 20, 2025 | tipranks.comUpexi (NASDAQ:UPXI) Trading Down 10% - Time to Sell?August 17, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Shares Gap Down - Here's What HappenedAugust 16, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Stock Rating Upgraded by Cantor FitzgeraldAugust 16, 2025 | marketbeat.comDigital Asset Treasury Firms Plunge as Bitcoin Tumbles Below $117K, ETH Slides to $4.4KAugust 15, 2025 | coindesk.comUpexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?August 15, 2025 | marketbeat.comFormer Amazon aggregator turns to Solana, records $70K in daily rewardsAugust 13, 2025 | msn.comUpexi establishes Advisory Committee, welcomes Hayes as first memberAugust 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCX, IMAB, UPXI, and RCKT Company DescriptionsI-Mab NASDAQ:IMAB$3.62 -0.47 (-11.49%) Closing price 04:00 PM EasternExtended Trading$3.62 0.00 (-0.14%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.OncoCyte NASDAQ:OCXOncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Rocket Pharmaceuticals NASDAQ:RCKT$3.22 +0.06 (+1.90%) Closing price 04:00 PM EasternExtended Trading$3.17 -0.05 (-1.68%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Upexi NASDAQ:UPXI$6.33 -0.43 (-6.36%) Closing price 04:00 PM EasternExtended Trading$6.37 +0.04 (+0.63%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
